Pangaea Oncology (XMAD:PANG) EPS (Basic): €-0.10 (TTM As of Dec. 2025)


XMAD:PANG Pangaea Oncology SA XMAD:PANG
67 GF Score
Price €1.56
GF Value €2.14
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology EPS (Basic)?

Pangaea Oncology XMAD:PANG 67 EPS (Basic) is €-0.10 as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 67/100 and a GF Value™ of €2.14 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Pangaea Oncology's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.10.

Pangaea Oncology's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.10.

Pangaea Oncology's EPS without NRI for the six months ended in Dec. 2025 was €-0.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.10.

During the past 3 years, the average EPS without NRI Growth Rate was -6.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -9.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Pangaea Oncology's highest 3-Year average EPS without NRI Growth Rate was 41.10% per year. The lowest was -96.20% per year. And the median was -8.70% per year.

Pangaea Oncology  (XMAD:PANG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pangaea Oncology EPS (Basic) Related Terms

Pangaea Oncology EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Pangaea Oncology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pangaea Oncology EPS (Basic) Chart

Pangaea Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.09 -0.15 -0.03 -0.10

Pangaea Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.05 0.01 -0.05 -0.05
XMAD:PANG
67GF Score
Pangaea Oncology SA XMAD:PANG
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pangaea Oncology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pangaea Oncology's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.596-0)/35.913
=-0.10

Pangaea Oncology's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.904-0)/35.913
=-0.05

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.10 mean?
Pangaea Oncology (XMAD:PANG) has a EPS (Basic) of €-0.10 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pangaea Oncology and its competitors.
Is Pangaea Oncology's EPS (Basic) too high?
Pangaea Oncology's current EPS (Basic) is €-0.10. Overall, Pangaea Oncology has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's EPS (Basic) compare to TMO and DHR?
Pangaea Oncology's EPS (Basic) of €-0.10 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pangaea Oncology and its competitors. Pangaea Oncology's current EPS (Basic) is €-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.14, compared to a current price of €1.56 — trading 27.1% below its estimated fair value. The current EPS (Basic) is €-0.10. Pangaea Oncology's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current EPS (Basic) is €-0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.56 is trading 27.1% below its estimated GF Value™ of €2.14. GuruFocus considers Pangaea Oncology to be Modestly Undervalued.

Key valuation signals for XMAD:PANG:

  • EPS (Basic): €-0.10
  • GF Value™: €2.14 vs. price of €1.56 (27.1% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
67GF Score

Get the complete analysis for XMAD:PANG

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.56
Price
€2.14
GF Value